durvalumab
astrazeneca
[]
 my phase-1 called the ire-c study is complete without any safety issues. we sandwiched the y90 around 5 doses of immunotherapy. accelerated titration design. liver may need alternative strategies. #gi20 #gi23 
Oncologist | Researcher | ColorectalCancer #CRCSM👨🏼‍🎓@MayoClinic @PittTweet Alum; 🧬#ctDNA #LiquidBiopsies💡#PrecisionOncology ViewsMy Own. COI @ASCO📍 #GI23